November 8, 2019 5:11pm

November continued with 4 positive and 2 negative closes as the IBB closed up +1.86% while the XBI closed up +2.08%

… Contributing to an Advance/Decline line of 29/11; don’t start rejoicing about appreciation, more earnings to follow which contribute to sentiment declines

The week’s “numbers” in review

In “our’ universe of cell and gene therapy, we are betting on the hope for a cure or a treatment but, we are dependent on the management team to represent our hopes and aspirations.  


 

Anyone who reads my newsletter knows that I am about making money, no matter what happens in the sector.

 

The Dow closed points UP +6.17 (+0.02%), the S&P closed UP +7.87 points (+0.26%) and the NASDAQ closed UP +40.80 points (+0.48%)

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday the IBB closed up +1.86% while the XBI closed up +2.08%
  • Thursday the IBB closed up +0.04% while the XBI closed up +0.21%
  • Wednesday the IBB closed down -1.21% while the XBI closed down -1.42%
  • Tuesday the IBB closed up +0.02% while the XBI closed flat at 0.00%
  • Monday the IBB closed down -0.35% while the XBI closed down -0.53%

 

The advance/decline line scenario of 45 covered companies:  

  • Friday the close was positive with an A/D line of 29/11, 2 flats, 1 reversed merged (HSGX) and 2 acquired;
  • Thursday the close was positive with an A/D line of 21/18, 3 flats, 1 reversed merged (HSGX) and 2 acquired;
  • Wednesday the close was negative with an A/D line of 13/27, 2 flats, 1 reversed merged (HSGX) and 2 acquired;
  • Tuesday the close was positive with an A/D line of 23/17, 2 flats, 1 reversed merged (HSGX) and 2 acquired;
  • Monday the close was negative with an A/D line of 18/22, 2 flats, 1 reversed merged (HSGX) and 2 acquired;

 

Henry’omics:

Indexes hovered around the flat line on Friday but remained on track for solid weekly gains after trade optimism sparked a massive rotation out of bonds and lifted equities to record levels.

  • A spokesperson for the Chinese Commerce Ministry said Thursday that China and the U.S. had agreed to cancel existing tariffs in phases. A U.S. official also reportedly said both sides agreed to roll back the levies in tranches.

The Dow is up (+1.1%), the S&P 500 (+0.6%) and NASDAQ (+0.8%) are up for the week. It would be the third straight week of gains for the Dow while the S&P 500 headed for its fifth straight weekly gain. The NASDAQ was on pace for a six-week winning streak.

 

Be ready for the next wave of the smaller cap sector equities announcing LPS (loss-per-share) numbers and ... runways!

 

Decliners:

  • Stemline Therapeutics (STML -$1.190;
  • Homology Medicine (FIXX -$0.44);
  • Editas Medicine (EDIT -$0.42);
  • Seneca Biopharma <formerly Neuralstem>(CUR - $0.31);
  • Global Blood therapeutics (GBT -$0.17);

Incliners:

  • Sage Therapeutics (SAGE +$7.47 after Thursday’s -$0.67 and Wednesday’s -$5.73);
  • bluebird bio (BLUE +$2.02 after Thursday’s -$2.04);
  • Ionis Pharmaceuticals (IONS +$1.71);
  • CRISPR Therapeutics (CRSP +$1.53 after Thursday’s +$1.18, Wednesday’s+$1.23, Tuesday’s -$1.56 and Monday’s -$2.12);
  • Audentes Therapeutics (BOLD +$1.49);

 

 

The percentage (%) indicators: 

  • Friday’s range of the 29 upside was +0.03% (ONCE) to +10.28% (ADRO) while the 11 downside ranged from -0.30% (BLFS) to -16.94% (CUR);

 

  • Thursday’s range of the 21 upside was +0.51% (SAGE) to +17.09% (AXGN) while the 18 downside ranged from -0.12% (GBT) to -27.47% (BLCM);

 

  • Wednesday’s range of the 13 upside was +0.25% (BMRN) to +7.31% (KOOL) while the 27 downside ranged from -0.07% (ONCE) to -16.94% (CUR);

 

  • Tuesday’s range of the 23 upside was +0.34% (ALNY) to +12.86% (VCEL) while the 17 downside ranged from -0.32% (ONVO) to -16.94% (CUR);

 

  • Monday’s range of the 18 upside was +0.09% (ONCE) to +19.63% (BLCM) while the 29 downside ranged from -0.07% (BMRN) to -16.94% (CUR);

 

 

Upside volume stats:  to compare

  • Friday: 8 out of the 29 upside had higher than the 3 month average volume;
  • Thursday: 5 out of the 21 upside had higher than the 3 month average volume;
  • Wednesday: 8 out of the 13 upside had higher than the 3 month average volume;
  • Tuesday: 5 out of the 23 upside had higher than the 3 month average volume;
  • Monday: 1 out of the 19 upside had higher than the 3 month average volume;

Downside volume stats:

  • Friday: 7 out of the 11 downside had higher than the 3 month average volume;
  • Thursday: 4 out of the 18 downside had higher than the 3 month average volume;
  • Wednesday: 8 out of the 27 downside had higher than the 3 month average volume;
  • Tuesday: 6 out of the 17 downside had higher than the 3 month average volume;
  • Monday: 1 out of the 22 downside had higher than the 3 month average volume;

 

2 flat – VSTM and RENE.L with 1 reverse merged (HSGX), 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche could be soon according to rumors from FTC by year’s end.

 

November’s sessions:

Friday closed POSITIVE with 11 decliners, 29 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed POSITIVE with 18 decliners, 21 advancers, 3 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 27 decliners, 13 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 17 decliners, 23 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with19 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 7 decliners, 33 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.